Here, we systematically evaluate the effects of fibroblast-conditioned medium on the response of a large panel of HER2+ breast cancer cell lines to the FDA-approved HER2 kinase inhibitor lapatinib. The gene discussed is ERBB2; the disease is breast cancer.